Scholarlink

Purpose of Review <p>Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential treatments for substance use disorders, including OUD. Psychedelics are typically administered alongside psychotherapy, though the role and necessity of concurrent psychotherapy remains a topic of debate. This review examines trials involving both classical and non-classical psychedelics for OUD treatment, aiming to evaluate the evidence for the importance of psychotherapy and identify the most effective therapeutic approaches, if any.</p> Recent Findings <p>No studies were identified that directly compared different psychotherapy modalities or assessed the effects of psychedelics with versus without concurrent psychotherapy. Most research examining the impact of psychedelics on alleviating opioid withdrawal symptoms did not incorporate a psychotherapy component. However, the few studies that investigated the effects of psychedelics (ketamine and LSD) on opioid use and abstinence adopted&#xa0; a psychedelic-assisted therapy model.</p> Summary <p>There is insufficient high-quality evidence to support or oppose the necessity of concurrent psychotherapy in psychedelic trials for OUD. Future clinical trials should be structured to explore the interplay between psychedelic treatment and psychotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • Anahita Bassir Nia,
  • Yalda Farahmand,
  • Garret Griffith,
  • Mohammad Aghaei Ardavan,
  • Gustavo A. Angarita,
  • Akhil Anand,
  • Christopher Pittenger

摘要

Purpose of Review

Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential treatments for substance use disorders, including OUD. Psychedelics are typically administered alongside psychotherapy, though the role and necessity of concurrent psychotherapy remains a topic of debate. This review examines trials involving both classical and non-classical psychedelics for OUD treatment, aiming to evaluate the evidence for the importance of psychotherapy and identify the most effective therapeutic approaches, if any.

Recent Findings

No studies were identified that directly compared different psychotherapy modalities or assessed the effects of psychedelics with versus without concurrent psychotherapy. Most research examining the impact of psychedelics on alleviating opioid withdrawal symptoms did not incorporate a psychotherapy component. However, the few studies that investigated the effects of psychedelics (ketamine and LSD) on opioid use and abstinence adopted  a psychedelic-assisted therapy model.

Summary

There is insufficient high-quality evidence to support or oppose the necessity of concurrent psychotherapy in psychedelic trials for OUD. Future clinical trials should be structured to explore the interplay between psychedelic treatment and psychotherapy.